4/A//SEC Filing
Trius Therapeutics Inc 4/A
Accession 0001209191-13-031712
CIK 0001356857operating
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 7:56 PM ET
Size
6.2 KB
Accession
0001209191-13-031712
Insider Transaction Report
Form 4/AAmended
Finn John
Chief Scientific Officer
Transactions
- Sale
Common Stock
2013-05-10$7.47/sh−3,000$22,425→ 186,860 total(indirect: By Trust)
Holdings
- 1,782
Common Stock
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2012
- [F2]The weighted average sales price for the transaction reported was $7.475, and the range of prices were between $7.10 and $7.55. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided
- [F3]This Form 4 is being amended to correctly reflect the holdings as indirectly held.
- [F4]This Form 4 is being amended to include direct holdings which were inadvertently omitted from the filing.
Documents
Issuer
Trius Therapeutics Inc
CIK 0001356857
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001356857
Filing Metadata
- Form type
- 4/A
- Filed
- Jun 10, 8:00 PM ET
- Accepted
- Jun 11, 7:56 PM ET
- Size
- 6.2 KB